Search
for
Sort by
Research 481–510 of 778
- Transcription factor-based transdifferentiation of human embryonic to trophoblast stem cells
- Cellular senescence and polycystic ovary syndrome: mechanisms and therapeutic strategies from a new perspective
- Extracellular Vesicles in Skin: Biological Function and Therapeutic Potential
- Inflammatory auxo-action in the stem cell division theory of cancer
- ApoBDs: a paradigm shift from cellular debris to therapeutic vehicles
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- 151 High effectiveness of tildrakizumab over 52 weeks in patients with or without nail psoriasis: results from the phase IV POSITIVE Austrian subset
- Recent advances in the genetics of alopecia areata
- Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome
- Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
- Medical Dermatology
- Three Types of Alopecia in One Patient: A Case of Central Centrifugal Cicatricial Alopecia, Alopecia Areata, and Telogen Effluvium
- Hair Disorders in Autoimmune Diseases
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: e-Posters
- Comprehensive single-cell transcriptomic profiling of the scalp from patients with moderate-to-severe alopecia areata
- Association between alopecia areata and cardiovascular disease: a systematic review and meta-analysis
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients